{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:43:38Z","timestamp":1791614618282,"version":"4.3.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230114"],"award-info":[{"award-number":["82230114"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204352"],"award-info":[{"award-number":["82204352"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171249"],"award-info":[{"award-number":["82171249"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2411078"],"award-info":[{"award-number":["2411078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02651-2","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:45:14Z","timestamp":1776840314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Temporal assessment of behavior in Parkinson\u2019s visual hallucinations via a multidimensional analysis strategy"],"prefix":"10.1038","volume":"11","author":[{"given":"Quan-Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9781-6281","authenticated-orcid":false,"given":"Yi-Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Wen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Jia","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Long","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukunaga","family":"Kohji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Feng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3187-4344","authenticated-orcid":false,"given":"Ying-Mei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4868-3491","authenticated-orcid":false,"given":"Feng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2651_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(18)30127-3","volume":"17","author":"J Marinus","year":"2018","unstructured":"Marinus, J., Zhu, K., Marras, C., Aarsland, D. & van Hilten, J. J. Risk factors for non-motor symptoms in Parkinson\u2019s disease. Lancet Neurol. 17, 559\u2013568 (2018).","journal-title":"Lancet Neurol."},{"key":"2651_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","volume":"15","author":"W Poewe","year":"2008","unstructured":"Poewe, W. Non-motor symptoms in Parkinson\u2019s disease. Eur. J. Neurol. 15, 14\u201320 (2008).","journal-title":"Eur. J. Neurol."},{"key":"2651_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41401-020-0373-y","volume":"41","author":"JL Waddington","year":"2020","unstructured":"Waddington, J. L. Psychosis in Parkinson\u2019s disease and parkinsonism in antipsychotic-naive schizophrenia spectrum psychosis: clinical, nosological and pathobiological challenges. Acta Pharmacol. Sin. 41, 464\u2013470 (2020).","journal-title":"Acta Pharmacol. Sin."},{"key":"2651_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G F\u00e9nelon","year":"2000","unstructured":"F\u00e9nelon, G., Mahieux, F., Huon, R. & Zi\u00e9gler, M. Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain 123, 733\u2013745 (2000).","journal-title":"Brain"},{"key":"2651_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/jnnp.70.6.727","volume":"70","author":"J Barnes","year":"2001","unstructured":"Barnes, J. & David, A. S. Visual hallucinations in Parkinson\u2019s disease: a review and phenomenological survey. J. Neurol. Neurosurg. Psychiatry 70, 727\u2013733 (2001).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2651_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0140-6736(01)06230-4","volume":"358","author":"AD Korczyn","year":"2001","unstructured":"Korczyn, A. D. Hallucinations in Parkinson\u2019s disease. Lancet 358, 1031\u20131032 (2001).","journal-title":"Lancet"},{"key":"2651_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","volume":"5","author":"NJ Diederich","year":"2009","unstructured":"Diederich, N. J., F\u00e9nelon, G., Stebbins, G. & Goetz, C. G. Hallucinations in Parkinson's disease. Nat. Rev. Neurol. 5, 331\u2013342 (2009).","journal-title":"Nat. Rev. Neurol."},{"key":"2651_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.euroneuro.2024.04.011","volume":"85","author":"Z Tipado","year":"2024","unstructured":"Tipado, Z., Kuypers, K. P. C., Sorger, B. & Ramaekers, J. G. Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions. Eur. Neuropsychopharmacol. 85, 10\u201320 (2024).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"2651_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jamaneurol.2023.1835","volume":"80","author":"E d\u2019Angremont","year":"2023","unstructured":"d\u2019Angremont, E., Begemann, M. J. H., van Laar, T. & Sommer, I. E. C. Cholinesterase inhibitors for treatment of psychotic symptoms in Alzheimer disease and Parkinson disease: a meta-analysis. JAMA Neurol. 80, 813\u2013823 (2023).","journal-title":"JAMA Neurol."},{"key":"2651_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal, J. H. et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199\u2013214 (1994).","journal-title":"Arch. Gen. Psychiatry"},{"key":"2651_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/17460441.2018.1394838","volume":"13","author":"ZT Sahli","year":"2018","unstructured":"Sahli, Z. T. & Tarazi, F. I. Pimavanserin: novel pharmacotherapy for Parkinson\u2019s disease psychosis. Expert. Opin. Drug Discov. 13, 103\u2013110 (2018).","journal-title":"Expert. Opin. Drug Discov."},{"key":"2651_CR12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly, B. S. & Lang, A. E. Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670\u20131683 (2014).","journal-title":"JAMA"},{"key":"2651_CR13","doi-asserted-by":"publisher","first-page":"S351","DOI":"10.1002\/mds.21683","volume":"22","author":"PT Francis","year":"2007","unstructured":"Francis, P. T. & Perry, E. K. Cholinergic and other neurotransmitter mechanisms in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies. Mov. Disord. 22, S351\u2013S357 (2007).","journal-title":"Mov. Disord."},{"key":"2651_CR14","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1126\/science.abf4740","volume":"372","author":"K Schmack","year":"2021","unstructured":"Schmack, K., Bosc, M., Ott, T., Sturgill, J. F. & Kepecs, A. Striatal dopamine mediates hallucination-like perception in mice. Science 372, 6537 (2021).","journal-title":"Science"},{"key":"2651_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cell.2020.03.020","volume":"181","author":"D Nutt","year":"2020","unstructured":"Nutt, D., Erritzoe, D. & Carhart-Harris, R. Psychedelic Psychiatry\u2019s Brave New World. Cell 181, 24\u201328 (2020).","journal-title":"Cell"},{"key":"2651_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.abl8615","volume":"375","author":"D Cao","year":"2022","unstructured":"Cao, D. et al. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science 375, 403\u2013411 (2022).","journal-title":"Science"},{"key":"2651_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic, J. Parkinson\u2019s disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368\u2013376 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2651_CR18","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1002\/mds.10567","volume":"18","author":"W Poewe","year":"2003","unstructured":"Poewe, W. Psychosis in Parkinson\u2019s disease. Mov. Disord. 18, S80\u2013S87 (2003).","journal-title":"Mov. Disord."},{"key":"2651_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1474-4422(05)70267-2","volume":"5","author":"S Rossi","year":"2006","unstructured":"Rossi, S., Bartalini, S. & Ulivelli, M. Antiparkinsonian drugs and visual hallucinations. Lancet Neurol. 5, 18\u201320 (2006).","journal-title":"Lancet Neurol."},{"key":"2651_CR20","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1001\/jama.1972.03200220084025","volume":"221","author":"RL Weinmann","year":"1972","unstructured":"Weinmann, R. L. Levodopa and hallucination. JAMA 221, 1054 (1972).","journal-title":"JAMA"},{"key":"2651_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.26432","volume":"31","author":"J Pagonabarraga","year":"2016","unstructured":"Pagonabarraga, J. et al. Minor hallucinations occur in drug-naive Parkinson\u2019s disease patients, even from the premotor phase. Mov. Disord. 31, 45\u201352 (2016).","journal-title":"Mov. Disord."},{"key":"2651_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/2045125317718810","volume":"8","author":"C Smart","year":"2018","unstructured":"Smart, C., McAllister-Williams, H. & Cousins, D. A. Acetylcholinesterase inhibitors in treatment-resistant psychotic depression. Ther. Adv. Psychopharmacol. 8, 59\u201361 (2018).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"2651_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1006\/brcg.1995.1255","volume":"28","author":"EK Perry","year":"1995","unstructured":"Perry, E. K. & Perry, R. H. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 28, 240\u2013258 (1995).","journal-title":"Brain Cogn."},{"key":"2651_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cpr.2017.05.001","volume":"57","author":"C Aynsworth","year":"2017","unstructured":"Aynsworth, C., Collerton, D. & Dudley, R. Measures of visual hallucinations: Review and recommendations. Clin. Psychol. Rev. 57, 164\u2013182 (2017).","journal-title":"Clin. Psychol. Rev."},{"key":"2651_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1126\/science.aav7893","volume":"364","author":"C Stringer","year":"2019","unstructured":"Stringer, C. et al. Spontaneous behaviors drive multidimensional, brainwide activity. Science 364, 255 (2019).","journal-title":"Science"},{"key":"2651_CR26","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.neuron.2023.02.003","volume":"111","author":"T Gschwind","year":"2023","unstructured":"Gschwind, T. et al. Hidden behavioral fingerprints in epilepsy. Neuron 111, 1440\u20131452 (2023).","journal-title":"Neuron"},{"key":"2651_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22970-y","volume":"12","author":"K Huang","year":"2021","unstructured":"Huang, K. et al. A hierarchical 3D-motion learning framework for animal spontaneous behavior mapping. Nat. Commun. 12, 2784 (2021).","journal-title":"Nat. Commun."},{"key":"2651_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-022-01434-9","volume":"20","author":"RZ Weber","year":"2022","unstructured":"Weber, R. Z., Mulders, G., Kaiser, J., Tackenberg, C. & Rust, R. Deep learning-based behavioral profiling of rodent stroke recovery. BMC Biol. 20, 232 (2022).","journal-title":"BMC Biol."},{"key":"2651_CR29","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1038\/s41592-024-02500-6","volume":"21","author":"LM von Ziegler","year":"2024","unstructured":"von Ziegler, L. M. et al. Analysis of behavioral flow resolves latent phenotypes. Nat. Methods 21, 2376\u20132387 (2024).","journal-title":"Nat. Methods"},{"key":"2651_CR30","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1016\/j.cub.2020.09.007","volume":"30","author":"R Storchi","year":"2020","unstructured":"Storchi, R. et al. A high-dimensional quantification of mouse defensive behaviors reveals enhanced diversity and stimulus specificity. Curr. Biol. 30, 4619\u20134630.e4615 (2020).","journal-title":"Curr. Biol."},{"key":"2651_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02481-8","volume":"13","author":"YT Tseng","year":"2023","unstructured":"Tseng, Y. T. et al. Systematic evaluation of a predator stress model of depression in mice using a hierarchical 3D-motion learning framework. Transl. Psychiatry 13, 178 (2023).","journal-title":"Transl. Psychiatry"},{"key":"2651_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/biomedicines10020355","volume":"10","author":"S Chiappini","year":"2022","unstructured":"Chiappini, S. et al. Misuse of anticholinergic medications: a systematic review. Biomedicines 10, 355 (2022).","journal-title":"Biomedicines"},{"key":"2651_CR33","first-page":"239","volume":"97","author":"DJ Palao","year":"1991","unstructured":"Palao, D. J., Ara\u00faxo, A. & Bernardo, M. Hallucinosis due to trihexyphenidyl abuse. Med. Clin. (Barc.). 97, 239 (1991).","journal-title":"Med. Clin. (Barc.)."},{"key":"2651_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1192\/bjp.145.3.300","volume":"145","author":"JA Crawshaw","year":"1984","unstructured":"Crawshaw, J. A. & Mullen, P. E. A study of benzhexol abuse. Br. J. Psychiatry 145, 300\u2013303 (1984).","journal-title":"Br. J. Psychiatry"},{"key":"2651_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1476-5381.1985.tb09461.x","volume":"86","author":"SL Handley","year":"1985","unstructured":"Handley, S. L. & Singh, L. Modulation of 5-hydroxytryptamine-induced head-twitch response by drugs acting at GABA and related receptors. Br. J. Pharmacol. 86, 297\u2013303 (1985).","journal-title":"Br. J. Pharmacol."},{"key":"2651_CR36","doi-asserted-by":"publisher","first-page":"112203","DOI":"10.1016\/j.celrep.2023.112203","volume":"42","author":"V Lewis","year":"2023","unstructured":"Lewis, V. et al. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep. 42, 112203 (2023).","journal-title":"Cell Rep."},{"key":"2651_CR37","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1007\/s00210-023-02778-x","volume":"397","author":"R Takaba","year":"2024","unstructured":"Takaba, R. et al. Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL\/6J male mice. Naunyn-Schmiedebergs Arch. Pharmacol. 397, 3019\u20133035 (2024).","journal-title":"Naunyn-Schmiedebergs Arch. Pharmacol."},{"key":"2651_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1176\/ajp.151.3.429","volume":"151","author":"DC Goff","year":"1994","unstructured":"Goff, D. C., Amico, E., Dreyfuss, D. & Ciraulo, D. A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. Am. J. Psychiatry 151, 429\u2013431 (1994).","journal-title":"Am. J. Psychiatry"},{"key":"2651_CR39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1192\/bjp.140.5.473","volume":"140","author":"Y Kaminer","year":"1982","unstructured":"Kaminer, Y., Munitz, H. & Wijsenbeek, H. Trihexyphenidyl (Artane) abuse: euphoriant and anxiolytic. Br. J. Psychiatry 140, 473\u2013474 (1982).","journal-title":"Br. J. Psychiatry"},{"key":"2651_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1021\/acschemneuro.8b00433","volume":"10","author":"AD Volgin","year":"2019","unstructured":"Volgin, A. D. et al. Understanding central nervous system effects of deliriant hallucinogenic drugs through experimental animal models. ACS Chem. Neurosci. 10, 143\u2013154 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"2651_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neunet.2014.09.001","volume":"62","author":"H Tsukada","year":"2015","unstructured":"Tsukada, H., Fujii, H., Aihara, K. & Tsuda, I. Computational model of visual hallucination in dementia with Lewy bodies. Neural Netw. 62, 73\u201382 (2015).","journal-title":"Neural Netw."},{"key":"2651_CR42","doi-asserted-by":"crossref","unstructured":"Berman, G. J., Choi, D. M., Bialek, W. & Shaevitz, J. W. Mapping the stereotyped behaviour of freely moving fruit flies. J. R. Soc. Interface. 11 (2014).","DOI":"10.1098\/rsif.2014.0672"},{"key":"2651_CR43","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1093\/eurheartj\/ehy436","volume":"39","author":"T Asano","year":"2018","unstructured":"Asano, T. et al. Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. Eur. Heart J. 39, 3381\u20133389 (2018).","journal-title":"Eur. Heart J."},{"key":"2651_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-018-0869-z","volume":"20","author":"SC Panchal","year":"2018","unstructured":"Panchal, S. C. & Ondo, W. G. Treating hallucinations and delusions associated with Parkinson\u2019s Disease psychosis. Curr. Psychiatry Rep. 20, 3 (2018).","journal-title":"Curr. Psychiatry Rep."},{"key":"2651_CR45","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1126\/science.adl0666","volume":"386","author":"J Muir","year":"2024","unstructured":"Muir, J. et al. Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states. Science 386, 802\u2013810 (2024).","journal-title":"Science"},{"key":"2651_CR46","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/3738","volume":"1","author":"DH Ffytche","year":"1998","unstructured":"Ffytche, D. H. et al. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat. Neurosci. 1, 738\u2013742 (1998).","journal-title":"Nat. Neurosci."},{"key":"2651_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1212\/WNL.0000000000005985","volume":"91","author":"M Onofrj","year":"2018","unstructured":"Onofrj, M. & Gilbert, G. J. GABA and hallucinations in Parkinson's disease: Who is that sitting on my chair? Neurology 91, 293\u2013294 (2018).","journal-title":"Neurology"},{"key":"2651_CR48","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/schbul\/sbz099","volume":"46","author":"H Hjelmervik","year":"2020","unstructured":"Hjelmervik, H. et al. Intra-Regional Glu-GABA vs Inter-Regional Glu-Glu Imbalance: A 1H-MRS Study of the Neurochemistry of Auditory Verbal Hallucinations in Schizophrenia. Schizophr. Bull. 46, 633\u2013642 (2020).","journal-title":"Schizophr. Bull."},{"key":"2651_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03611-0","volume":"15","author":"GP Schmitz","year":"2025","unstructured":"Schmitz, G. P. et al. Psychedelic compounds directly excite 5-HT(2A) layer V medial prefrontal cortex neurons through 5-HT(2A) Gq activation. Transl. Psychiatry 15, 381 (2025).","journal-title":"Transl. Psychiatry"},{"key":"2651_CR50","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40265-016-0597-9","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham, A. Pimavanserin: first global approval. Drugs 76, 1053\u20131057 (2016).","journal-title":"Drugs"},{"key":"2651_CR51","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1056\/NEJMe2109010","volume":"385","author":"JI Friedman","year":"2021","unstructured":"Friedman, J. I. Pimavanserin in Dementia-related psychosis. N. Engl. J. Med. 385, 372\u2013373 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2651_CR52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings, J. et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383, 533\u2013540 (2014).","journal-title":"Lancet"},{"key":"2651_CR53","first-page":"e12247","volume":"8","author":"H Jimenez","year":"2022","unstructured":"Jimenez, H. et al. The impact of pimavanserin on psychotic phenotypes and tau phosphorylation in the P301L\/COMT- and rTg(P301L)4510 mouse models of Alzheimer\u2019s disease. Alzheimers Dement. 8, e12247 (2022).","journal-title":"Alzheimers Dement."},{"key":"2651_CR54","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1212\/WNL.55.2.281","volume":"55","author":"I Arnulf","year":"2000","unstructured":"Arnulf, I. et al. Hallucinations, REM sleep, and Parkinson\u2019s disease: a medical hypothesis. Neurology 55, 281\u2013288 (2000).","journal-title":"Neurology"},{"key":"2651_CR55","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41593-020-0591-0","volume":"23","author":"N Daviu","year":"2020","unstructured":"Daviu, N. et al. Paraventricular nucleus CRH neurons encode stress controllability and regulate defensive behavior selection. Nat. Neurosci. 23, 398\u2013410 (2020).","journal-title":"Nat. Neurosci."},{"key":"2651_CR56","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","volume":"70","author":"S Holroyd","year":"2001","unstructured":"Holroyd, S., Currie, L. & Wooten, G. F. Prospective study of hallucinations and delusions in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 70, 734\u2013738 (2001).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2651_CR57","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"LX Shao","year":"2021","unstructured":"Shao, L. X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in the frontal cortex in vivo. Neuron 109, 2535\u20132544.e2534 (2021).","journal-title":"Neuron"},{"key":"2651_CR58","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., B\u00e4bler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9, 3897\u20133902 (1998).","journal-title":"Neuroreport"},{"key":"2651_CR59","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1097\/NEN.0000000000000014","volume":"72","author":"DH Hepp","year":"2013","unstructured":"Hepp, D. H. et al. Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients. J. Neuropathol. Exp. Neurol. 72, 1162\u20131170 (2013).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2651_CR60","first-page":"Cd003735","volume":"2002","author":"R Katzenschlager","year":"2003","unstructured":"Katzenschlager, R., Sampaio, C., Costa, J. & Lees, A. Anticholinergics for symptomatic management of Parkinson\u2019s disease. Cochrane Database Syst. Rev. 2002, Cd003735 (2003).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2651_CR61","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/brain\/awab446","volume":"145","author":"S Smaji\u0107","year":"2022","unstructured":"Smaji\u0107, S. et al. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain 145, 964\u2013978 (2022).","journal-title":"Brain"},{"key":"2651_CR62","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1212\/01.WNL.0000141853.27081.BD","volume":"63","author":"GT Stebbins","year":"2004","unstructured":"Stebbins, G. T. et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 63, 1409\u20131416 (2004).","journal-title":"Neurology"},{"key":"2651_CR63","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s42003-023-05093-6","volume":"6","author":"I Brys","year":"2023","unstructured":"Brys, I. et al. 5-HT2AR and NMDAR psychedelics induce similar hyper-synchronous states in the rat cognitive-limbic cortex-basal ganglia system. Commun. Biol. 6, 737 (2023).","journal-title":"Commun. Biol."},{"key":"2651_CR64","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41593-020-00706-3","volume":"23","author":"AB Wiltschko","year":"2020","unstructured":"Wiltschko, A. B. et al. Revealing the structure of pharmacobehavioral space through motion sequencing. Nat. Neurosci. 23, 1433\u20131443 (2020).","journal-title":"Nat. Neurosci."},{"key":"2651_CR65","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41380-022-01913-z","volume":"28","author":"Y Shemesh","year":"2023","unstructured":"Shemesh, Y. & Chen, A. A paradigm shift in translational psychiatry through rodent neuroethology. Mol. Psychiatry 28, 993\u20131003 (2023).","journal-title":"Mol. Psychiatry"},{"key":"2651_CR66","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/01.JGP.0000192480.89813.80","volume":"14","author":"UP Mosimann","year":"2006","unstructured":"Mosimann, U. P. et al. Characteristics of visual hallucinations in Parkinson's disease dementia and dementia with Lewy bodies. Am. J. Geriatr. Psychiatry 14, 153\u2013160 (2006).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"2651_CR67","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1093\/brain\/awae186","volume":"147","author":"E d\u2019Angremont","year":"2024","unstructured":"d\u2019Angremont, E. et al. Cholinergic deficiency in Parkinson\u2019s disease patients with visual hallucinations. Brain 147, 3370\u20133378 (2024).","journal-title":"Brain"},{"key":"2651_CR68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","volume":"76","author":"MR Picciotto","year":"2012","unstructured":"Picciotto, M. R., Higley, M. J. & Mineur, Y. S. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron 76, 116\u2013129 (2012).","journal-title":"Neuron"},{"key":"2651_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/srep36284","volume":"6","author":"S Lefebvre","year":"2016","unstructured":"Lefebvre, S. et al. Hallucinations and conscious access to visual inputs in Parkinson\u2019s disease. Sci. Rep. 6, 36284 (2016).","journal-title":"Sci. Rep."},{"key":"2651_CR70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland, D. et al. Parkinson's disease-associated cognitive impairment. Nat. Rev. Dis. Prim. 7, 47 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2651_CR71","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1750-1326-9-17","volume":"9","author":"X Lu","year":"2014","unstructured":"Lu, X., Kim-Han, J. S., Harmon, S., Sakiyama-Elbert, S. E. & O\u2019Malley, K. L. The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons. Mol. Neurodegener. 9, 17 (2014).","journal-title":"Mol. Neurodegener."},{"key":"2651_CR72","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","volume":"65","author":"D Blum","year":"2001","unstructured":"Blum, D. et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson\u2019s disease. Prog. Neurobiol. 65, 135\u2013172 (2001).","journal-title":"Prog. Neurobiol."},{"key":"2651_CR73","doi-asserted-by":"publisher","first-page":"0121","DOI":"10.34133\/research.0121","volume":"6","author":"C Tong","year":"2023","unstructured":"Tong, C. et al. Striatal CDK5 regulates Cholinergic neuron activation and Dyskinesia-like behaviors through BK channels. Research 6, 0121 (2023).","journal-title":"Research"},{"key":"2651_CR74","doi-asserted-by":"publisher","first-page":"110180","DOI":"10.1016\/j.neuropharm.2024.110180","volume":"262","author":"S Alimohammadi","year":"2025","unstructured":"Alimohammadi, S. et al. Intranasal AdipoRon mitigates motor and cognitive deficits in hemiparkinsonian rats through neuroprotective mechanisms against oxidative stress and synaptic dysfunction. Neuropharmacology 262, 110180 (2025).","journal-title":"Neuropharmacology"},{"key":"2651_CR75","doi-asserted-by":"publisher","first-page":"7988","DOI":"10.1038\/s41586-023-06814-x","volume":"623","author":"S Ma","year":"2023","unstructured":"Ma, S. et al. Author Correction: Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb. Nature 623, 7988 (2023).","journal-title":"Nature"},{"key":"2651_CR76","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s12264-022-00834-9","volume":"38","author":"K Huang","year":"2022","unstructured":"Huang, K. et al. An easily compatible eye-tracking system for freely-moving small animals. Neurosci. Bull. 38, 661\u2013676 (2022).","journal-title":"Neurosci. Bull."},{"key":"2651_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48257-6","volume":"15","author":"AE Freitas","year":"2024","unstructured":"Freitas, A. E. et al. Planar cell polarity proteins mediate ketamine-induced restoration of glutamatergic synapses in prefrontal cortical neurons in a mouse model for chronic stress. Nat. Commun. 15, 4945 (2024).","journal-title":"Nat. Commun."},{"key":"2651_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70380","volume":"15","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. T-cell differentiation stage block bias confers hypermethylation and mediastinal preference in T-cell lymphoblastic lymphoma. Clin. Transl. Med. 15, e70380 (2025).","journal-title":"Clin. Transl. Med."},{"key":"2651_CR79","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-022-00989-x","volume":"7","author":"XX Liu","year":"2022","unstructured":"Liu, X. X. et al. BOD1 regulates the cerebellar IV\/V lobe-fastigial nucleus circuit associated with motor coordination. Signal. Transduct. Target. Ther. 7, 170 (2022).","journal-title":"Signal. Transduct. Target. Ther."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02651-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02651-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02651-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:04:26Z","timestamp":1776845066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02651-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2651"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02651-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}